Here's some of the condensed and repeated press release, from the UK outlets:
. . . .Merck on Tuesday announced that Keytruda (pembrolizumab), the company's anti-PD-1 therapy, has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy.
The approval is based on data from the phase 3 KEYNOTE-045 trial, which demonstrated superior overall survival for KEYTRUDA versus investigator-choice chemotherapy. With the approval, KEYTRUDA is now indicated for use in four types of cancer in Japan. . . .
Onward now, and though still bitterly icy cold here, the stark sunshine has me smiling in a thoughtful, sentient way. . . indeed. So, I'll offer some newly minted 2018 prose. . . . as I look out over the lake, from 29 floors above.
The nearly ancient and completely darkened but still solid gold miniature shipwrecks (once in a butterfly-like silk bag -- long lost -- and now sent along, out the locks) must forever lie in silence, under several hundred feet of ice and clear but frigid Lake Michigan water -- but they know. . . they well know who they are (or were) -- as you know who you are. And were -- now coming up on six-, or twenty-years on. Onward. Ever onward. . . .
नमस्ते
No comments:
Post a Comment